CDMO Lonza has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS), the company said. In the announcement of its IPAC-RS membership, Lonza specifically noted its planned participation in discussions related to particle engineering, inhaler testing, devices, and packaging.
In July 2020, Lonza announced that it had established a new DPI development Center of Excellence at its site in Bend, OR, USA. In addition to Lonza’s contract development and manufacturing services for OINDPs, the company also manufactures and markets DPI capsules under the Capsugel brand. Lonza acquired Capsugel in 2017; launched Capsugel Zephyr DPI capsules in 2019; and added DPI capsule manufacturing capacity in 2020.
Lonza Technology Head, Respiratory Delivery, Matthew Ferguson commented, “Locally administered drug products represent an attractive means of delivery for lung indications thanks to their decreased off-target activity. However, the development of stable dry powder formulations remains a challenge. Lonza’s participation in the IPAC-RS consortium will enable us to contribute to discussions on regulatory guidance that will improve the manufacturing process of these innovative products globally.”
Lonza Executive Director, Commercial Development, Small Molecules, Jason Bertola said, “Drug delivery via the lung is complex but gaining importance in the market with significant opportunities in unmet clinical needs. This results in increasing demand for formulation development, particle engineering and manufacturing of inhalation products, with an emphasis on speed. At Lonza, we understand this challenge and plan to contribute and further our expertise in this area to better serve our customers.”
Read the Lonza press release.
